Cardiovascular Department, Ferrarotto Hospital, University of Catania, Catania, Italy.
Am Heart J. 2010 Nov;160(5):973-8. doi: 10.1016/j.ahj.2010.07.002.
Although drug-eluting stents (DES) have reduced restenosis in a broad range of lesions, there is limited data, from relatively small studies, on the safety and efficacy of DES for isolated ostial left anterior descending (LAD) stenoses. In addition, in the setting of these high-risk lesions, there is the issue of the potential involvement of the left main (LM) bifurcation, requiring subsequent revascularization for a lesion involving this critical location.
Patients with a de novo isolated unprotected ostial LAD stenoses treated with DES were included. Evaluated end points were cardiac death, nonfatal myocardial infarction, overall target lesion revascularization (TLR), and the reintervention for a restenotic lesion located at the LM segment adjacent to the stent (TLR-LM).
A total of 162 patients were included: 95 underwent focal ostial LAD stenting and 67 stenting from the distal LM into the LAD ostium. The 2-year Kaplan-Meier estimates of cardiac death, nonfatal myocardial infarction, overall TLR, and TLR-LM were 2.6%, 2.1%, 8.3%, and 4.7%, respectively. Overall TLR and TLR-LM rates were higher in the focal ostial LAD stenting group. There was a trend toward an independent increased risk of TLR associated with focal ostial stenting. In addition, final minimal luminal diameter trended to be independently associated with TLR.
The present study showed that DES for isolated ostial LAD lesions is a feasible, safe, and effective treatment strategy. In addition, this study suggested the hypothesis that a default distal LM-LAD stenting, rather than focal ostial stenting, might provide more favorable outcomes. Nevertheless, larger specifically designed studies are needed.
尽管药物洗脱支架(DES)降低了广泛病变的再狭窄率,但来自相对较小研究的有限数据表明,DES 治疗孤立的左前降支(LAD)开口狭窄的安全性和有效性。此外,在这些高风险病变的情况下,存在涉及左主干(LM)分叉的潜在问题,需要对涉及这一关键部位的病变进行后续血运重建。
本研究纳入了接受 DES 治疗的新发孤立无保护的 LAD 开口狭窄患者。评估的终点事件包括心脏死亡、非致死性心肌梗死、总靶病变血运重建(TLR)以及支架相邻 LM 段再狭窄病变的再介入治疗(TLR-LM)。
共纳入 162 例患者:95 例行局灶性 LAD 开口支架置入术,67 例行远端 LM 至 LAD 开口支架置入术。2 年 Kaplan-Meier 估计的心脏死亡、非致死性心肌梗死、总 TLR 和 TLR-LM 分别为 2.6%、2.1%、8.3%和 4.7%。局灶性 LAD 开口支架置入组的总 TLR 和 TLR-LM 发生率较高。局灶性开口支架置入与 TLR 独立相关,存在趋势性增加风险。此外,最终最小管腔直径也与 TLR 呈独立相关。
本研究表明,DES 治疗孤立的 LAD 开口病变是一种可行、安全且有效的治疗策略。此外,本研究提出了一个假设,即默认的远端 LM-LAD 支架置入术而不是局灶性开口支架置入术可能提供更有利的结果。然而,需要进行更大规模的专门设计研究。